Kiromic Biopharma (KRBPQ) AI Stock Analysis

Top Page

Kiromic Biopharma

(Other OTC:KRBPQ)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Innovative Technology PlatformsKiromic Biopharma's focus on proprietary technology platforms in immuno-oncology positions it to potentially revolutionize cancer treatment, offering long-term competitive advantages in the biotechnology sector.

Negative Factors

Increasing LossesRising losses reflect high R&D expenses without offsetting revenue, challenging Kiromic's financial sustainability and necessitating strategic pivots to achieve profitability.

Kiromic Biopharma (KRBPQ) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $157
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.1
Beta (1Y): 15.92
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 44
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Kiromic Biopharma Business Overview & Revenue Model

Company Description

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The...

How the Company Makes Money

Kiromic Biopharma makes money primarily through the development and commercialization of its immuno-oncology products. The company generates revenue by licensing its technology platforms and collaborating with pharmaceutical companies to develop new...

Kiromic Biopharma Technical Analysis

Technical Analysis SentimentNeutral

Last Price0.04

Price Trends

Market Momentum

MACD-0.00Neutral

RSI44.56Neutral

STOCH71.43Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRBPQ, the sentiment is Neutral. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, compared to the 50-day MA of , and compared to the 200-day MA of , indicating a neutral trend. The MACD of -0.00 indicates Neutral momentum. The RSI at 44.56 is Neutral, neither overbought nor oversold. The STOCH value of 71.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KRBPQ.

Kiromic Biopharma Risk Analysis

Kiromic Biopharma disclosed 51 risk factors in its most recent earnings report. Kiromic Biopharma reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.Serious adverse events, including patient deaths in our clinical trials could delay or prevent regulatory approval and impact our business.Q4, 2024

Kiromic Biopharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

KRBPQ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AZTR	42Neutral	$4.66M	-0.06	-205.45%	―	―	78.16%
DRMA	42Neutral	$3.84M	-0.18	-166.67%	―	―	88.77%
SCNI	37Underperform	$268.82K	0.00	-26.63%	―	30.12%	-165.46%

* Healthcare Sector Average

Performance Comparison

KRBPQ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
KRBPQ	Kiromic Biopharma, Inc.	0.04	0.00	0.00%
SCNI	Scinai Immunotherapeutics Ltd. Sponsored Adr	0.47	-12.23	-96.29%
ADTX	Aditxt, Inc.	0.04	-1406.12	-100.00%
DRMA	Dermata Therapeutics, Inc.	0.78	-2.65	-77.34%
CERO	Cero Therapeutics Holdings, Inc.	0.01	-0.11	-91.74%
AZTR	Azitra Inc	0.77	-4.14	-84.35%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Kiromic Biopharma AI Stock Analysis

Top Page